Individualized Infiximab Dosing-Proof of Concept Study

Status unconfirmed

Conditions studied: Inflammatory Bowel Diseases

In brief

The purpose of this study is to determine which early infliximab pharmacokinetic level is most associated with clinical remission at weeks 30 and 54 in pediatric IBD patients.

Key facts

Study ID

NCT02027727

Run by

Cedars-Sinai Medical Center

People needed

56

Starts

2013-11-01

Expected to finish

2018-03-01

Last updated by the study team

2017-07-19

Who can join

Age: 6 and older, up to 23. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females on IFX
• Patients with IBD
• Age 6-23
• Able to obtain consent

You may not qualify if…

• Not receiving infliximab
• On 10 mg/kg of IFX
• Not able to obtain consent

Where it is running

• Cedars Sinai Medical Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.